That means companies such as Lilly, Novo Nordisk, Sanofi and AstraZeneca will soon ... management system combines a connected insulin pen with glucose-sensing technologies (e.g., glucose meter ...

Novo Nordisk has made its smart insulin pens available in the UK ... The Danish pharma is trying to stay ahead of arch rivals Eli Lilly and Sanofi in an increasingly competitive insulin market ...

injection Novolog (Novo Nordisk) 28 days Prescribing information Insulin glargine (rDNA origin) vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% ...

In 2023, the global disposable pen injectors market is expected to be worth USD 25.5 billion. The market is expected to reach USD 54.4 billion by 2033, expanding at a 7.9% CAGR throughout the forecast ...

The global insulin delivery pen market is poised for remarkable growth, with its valuation projected to increase from USD ...

The defendants listed include the drug manufacturers Eli Lilly, Novo Nordisk and Sanofi Aventis U.S., and PBM and group purchasing organization affiliates of Cigna's Evernorth Health unit ...

Today, we're tracking presentations from GSK, Novartis, Sanofi, Eli Lilly and other companies. 4:45 p.m. ET As Bayer braces for the loss of Xarelto's exclusivity, the company is turning to new ...

Hello, everyone, and how are you today? We are doing just fine, thank you, especially since the middle of the week is upon us. After all, we have made it this far so we are determined to hang on ...

“They need to fix it” before negotiating down the price of more drugs, Eli Lilly chief executive officer Dave Ricks said on the sidelines of the J.P. Morgan Healthcare Conference in San ...